Loading quotes...

Forecast

There is no analyst data available for this company.


  • Teijin beats sales forecasts in quarter, stock rises sharply

    Teijin reported fourth-quarter 2025 sales of ¥213.31 billion, beating expectations by 4.82%. Despite a negative earnings per share of -¥150.52, the share price climbed 9.22% to ¥1,711.5. The healthcare segment showed strong growth while the materials business lagged; management is pushing a strategic shift toward customer‑centric solutions. For fiscal 2025, total sales fell to ¥873.2 billion, and Teijin still expects profitability challenges but sees opportunities from restructuring and a focus on Healthcare and Electronics & Energy. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Teijin has already paid €0.13 in dividends. The last payout was in May.

Financials

In the last quarter, Teijin had revenue of €1.2B and net profit of €243.01M
(EUR) June 2026
YoY
Revenue 1.2B 16.64%
Gross profit 315.81M 4.22%
Net profit 243.01M 5,666.24%
EBITDA 119.36M 0.03%

Fundamentals

Metric Value
Market capitalization
€1.76B
Number of shares
192.92M
52-week high/low
€10.34 - €6.81
Dividend yield
2.98%
Dividends TTM
€0.27
Beta
0.32
P/E ratio
-7.37
PEG ratio
0.01
P/B ratio
0.75
P/S ratio
0.36

Company profile

Teijin Limited engages in the fibers, films and sheets, composites, healthcare, and IT businesses worldwide. It offers aramid fibers and polyethylene materials; carbon fibers, composite materials, and oxidized PAN fibers; polycarbonate sheets and films; high-density polyethylene porous films and materials; and microporous films. The company also provides PC resins, polyphenylene sulfide resins, molded parts, and additives; lightweight glass and carbon fiber reinforced composites for automotive applications; and polytrimethylene telephthalate products, artificial leather materials, polyester nanofibers, and recycled polyester fibers. In addition, it offers pharmaceuticals for bone and joint, respiratory, cardiovascular and metabolic, and other diseases; home oxygen therapy, non-invasive positive pressure ventilation, rehabilitation, and sleep disordered breathing related devices, as well as sonic accelerated fracture healing system and community-based integrated care system; and orthopedic implantable devices, and functional food ingredients. Further, the company provides Recopic, a radio-frequency identification technology for inventory management. Additionally, it develops and implements engineering solutions for various issues, such as environmental pollution, energy supply stability, and aging-related workforce population decline. Teijin Limited was incorporated in 1918 and is headquartered in Tokyo, Japan.

Name
Teijin
CEO
Akimoto Uchikawa
Headquarters Tokyo, ty
Japan
Website
IPO
01/07/2014
Employees 15,689

Ticker symbols

Exchange Symbol
Japan Exchange Group
3401.T
Pnk
TINLF
Frankfurt
TIJ.F
Düsseldorf
TIJ.DU
München
TIJ.MU
🍪

Parqet  uses cookies. Learn more